GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (STU:82P) » Definitions » Cyclically Adjusted PS Ratio

Pacira BioSciences (STU:82P) Cyclically Adjusted PS Ratio : 2.62 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pacira BioSciences Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Pacira BioSciences's current share price is €26.20. Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €10.00. Pacira BioSciences's Cyclically Adjusted PS Ratio for today is 2.62.

The historical rank and industry rank for Pacira BioSciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:82P' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.35   Med: 5.49   Max: 12.28
Current: 2.56

During the past years, Pacira BioSciences's highest Cyclically Adjusted PS Ratio was 12.28. The lowest was 2.35. And the median was 5.49.

STU:82P's Cyclically Adjusted PS Ratio is ranked worse than
58.41% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs STU:82P: 2.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pacira BioSciences's adjusted revenue per share data for the three months ended in Mar. 2024 was €2.946. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €10.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pacira BioSciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Pacira BioSciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Cyclically Adjusted PS Ratio Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.84 9.56 7.73 4.05 3.13

Pacira BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 3.87 2.87 3.13 2.62

Competitive Comparison of Pacira BioSciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PS Ratio falls into.



Pacira BioSciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pacira BioSciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=26.20/10
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pacira BioSciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.946/131.7762*131.7762
=2.946

Current CPI (Mar. 2024) = 131.7762.

Pacira BioSciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.979 100.560 1.283
201409 1.124 100.428 1.475
201412 1.389 99.070 1.848
201503 1.290 99.621 1.706
201506 1.272 100.684 1.665
201509 1.351 100.392 1.773
201512 1.554 99.792 2.052
201603 1.588 100.470 2.083
201606 1.667 101.688 2.160
201609 1.632 101.861 2.111
201612 1.846 101.863 2.388
201703 1.705 102.862 2.184
201706 1.572 103.349 2.004
201709 1.396 104.136 1.767
201712 1.646 104.011 2.085
201803 1.486 105.290 1.860
201806 1.727 106.317 2.141
201809 1.744 106.507 2.158
201812 2.032 105.998 2.526
201903 1.960 107.251 2.408
201906 2.144 108.070 2.614
201909 2.282 108.329 2.776
201912 2.637 108.420 3.205
202003 2.235 108.902 2.704
202006 1.588 108.767 1.924
202009 2.253 109.815 2.704
202012 2.407 109.897 2.886
202103 2.175 111.754 2.565
202106 2.468 114.631 2.837
202109 2.388 115.734 2.719
202112 3.097 117.630 3.469
202203 3.089 121.301 3.356
202206 3.054 125.017 3.219
202209 3.691 125.227 3.884
202212 3.534 125.222 3.719
202303 3.259 127.348 3.372
202306 3.005 128.729 3.076
202309 2.950 129.860 2.994
202312 2.413 129.419 2.457
202403 2.946 131.776 2.946

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pacira BioSciences  (STU:82P) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pacira BioSciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (STU:82P) Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

Pacira BioSciences (STU:82P) Headlines

No Headlines